All 10 patients who received the CTL119 cells experienced mild cytokine release syndrome (CRS), a known potentially lethal type of toxicity, within a few days after receiving their infusions; however, none required treatment with tocilizumab, an immunosuppressant drug that blocks the effects of the inflammatory cytokine IL - 6. (sciencedaily.com)
The researchers gave one participant in the study, who had already lost the use of one eye, a drug called tocilizumab to block interleukin - 6 after reattaching her retina. (sciencedaily.com)
Nine patients were treated with tocilizumab, an immunosuppressant drug that blocks the effects of the inflammatory cytokine IL - 6, which have been found to spike during the most robust phase of the engineered cells» expansion in the body. (sciencedaily.com)